Tag Archives: Alfacell Corporation
New Treatments Being Developed for Asbestos-Related Cancer
Mesothelioma is a particularly rare, aggressive, and deadly form of cancer that is typically found in individuals who have experienced an environmental exposure to asbestos. Asbestos is a naturally occurring, fibrous silicate mineral that can be found in several forms, including chrysotile and tremolite asbestos, though, all varieties of the material are currently listed as [...]
Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE
Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R) SOMERSET, N.J., Feb. 21 /PRNewswire-FirstCall/ — Alfacell Corporation (Nasdaq: ACEL – News) today announced that in vitro and in vivo data presented at the 5th Cancer Drug Research & Development conference show the genes affected and biological pathways impacted by ONCONASE stimulated intracellular events as revealed by [...]
Alfacell Updates Status Of ONCONASE(R) Phase III Clinical Program
Source: MedicalNewsToday.com Alfacell Corporation announced it has confirmed that 290 evaluable events (patient deaths) have occurred in the Phase IIIb clinical trial of its lead compound, ONCONASE, for the treatment of patients with unresectable malignant mesothelioma. The number of evaluable events was confirmed after the company learned that total events in the study had reached [...]
ONCONASE(R) has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
Source: Alfacell Corporation, BLOOMFIELD, N.J., April 18 /PRNewswire-FirstCall/ — ONCONASE (ranpirnase), Alfacell Corporation’s lead drug candidate, may have potential as a chemopreventive agent, according to world-renowned mesothelioma researcher Michele Carbone M.D., Ph.D., at this week’s American Association for Cancer Research (AACR) Annual Meeting. In a series of poster presentations, Dr. Carbone highlighted the growing worldwide [...]
Researchers Identify Intracellular Pathway of Alfacell's Onconase
Paper Published in Journal of Cell Science Shows ONCONASE Uptake in Cells Differs from other RNases BLOOMFIELD, N.J., April 05, 2007 /PRNewswire-FirstCall/ — Alfacell Corporation today announced that European researchers have identified the pathway that ONCONASE (ranpirnase) follows to enter cells. Published in the Journal of Cell Science (2007; 120: 1405-1411), a paper based on [...]
Alfacell Corporation Granted U.S. Orphan Drug Designation for ONCONASE® for Treatment of Malignant Mesothelioma
Source: Alfacell Corporation, January 30, 2007 First-in-Class RNAi Drug in Phase IIIB Confirmatory Trial for Unresectable Malignant Mesothelioma BLOOMFIELD, N.J., Jan. 30 /PRNewswire-FirstCall/ — Alfacell Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease therapeutics for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug [...]
Alfacell Corporation Files for U.S. Orphan Drug Designation for Onconase
Source: Alfacell Corporation, December 21, 2006 BLOOMFIELD, N.J. — Alfacell Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease therapeutics for cancer, today announced it has filed an application with the U.S. Food and Drug Administration (FDA) to obtain orphan designation for its lead drug candidate ONCONASE® (ranpirnase) for the [...]
Further Analysis of Phase III Data Using CALGB and EORTC Paradigms Reinforces Survival Benefits of ONCONASE(R) for the Treatment of Patients With Mesothelioma
Source: PhameLive, October 24, 2006 Alfacell Corporation today announced results from further detailed analysis of the company’s previously reported Phase IIIa clinical trial of ONCONASE® (ranpirnase) versus doxorubicin for the treatment of unresectable malignant mesothelioma (UMM). The post-hoc analysis found that patients treated with ONCONASE had greater median survival times than patients treated with doxorubicin [...]
New Research Findings Published in National Academy of Sciences Journal Show Unique Promise of ONCONASE in the Prevention and Treatment of Mesothelioma and Lung Cancer Caused by Asbestos
Press Release from Alfacell Corporation BLOOMFIELD, N.J., /PRNewswire-FirstCall/ — Alfacell Corporation announced today that groundbreaking, independent new research findings show that the elusive molecular mechanism that asbestos uses to provoke lung cancer may have been identified. The research also found that ONCONASE® (ranpirnase) may be one of the most effective methods of treatment for mesothelioma [...]
Alfacell Provides Update on ONCONASE Phase IIIb Confirmatory Registration Trial; Releases First Interim Analysis Data
Press Release from Alfacell Corporation April 27, 2006 BLOOMFIELD, N.J., April 27 /PRNewswire-FirstCall/ — Alfacell Corporation today announced that the 210 events (deaths) has been reached in its confirmatory Phase IIIb registration trial evaluating ONCONASE® (ranpirnase), the Company’s lead investigational drug candidate, as a treatment for unresectable malignant mesothelioma (UMM). This number of events represents [...]
